The US Food and Drug Administration (FDA) and the National Institute of Health (NIH) have announced they are partnering with the Critical Path Institute (C-Path) to promote research into rare neurodegenerative conditions. The agencies will work with the non-profit organization to advance individualized therapeutic development and collect a central repository of research and patient data for rare neurological disorders.
According to Emily Kimber, “The FDA outlined that this will ‘facilitate the characterisation of neurodegenerative diseases and their natural history, the identification of molecular targets for neurodegenerative disease, and increased efficiency, predictability, and productivity of clinical development of therapies’.”
To read more, click here.
(Source: PM Live, September 15th, 2022)